In April 2007, then-vice premier Tsai Ing-wen (蔡英文) approved an investment by the National Development Fund in Yu Chang Biologics Co, a new biotechnology company, in order to support Taiwan’s next key industry. In economic terms, that has proven to be the right decision.
However, the future of the biotechnology industry was still uncertain at the time and Yu Chang had problems raising funding. For the sake of Taiwan’s future, Academia Sinica president Wong Chi-huey (翁啟惠), world-renowned AIDS researcher David Ho (何大一) and F. Hoffmann-La Roche head of global technical operations Patrick Yang (楊育民) stepped up to the plate.
Convinced by these scientists, Tsai — who had already stepped down from her post as vice premier — raised the shortfall in capital from family members and served as the company’s unpaid chairwoman. The scientists turned to Tsai because of her image of neutrality and integrity as well as her experience as an international negotiator.
That biotechnology company, now named TaiMed Biologics, is the driving force behind Taiwan’s biotechnology industry, and it could yet invent the nation’s first anti-HIV drug. In this context, the company’s significance to Taiwan by far supersedes its business importance. Ho has said that if the company is successful, its success would not be measured in monetary terms.
Unfortunately, those in power are doing all they can to attack Tsai for the sake of the presidential election. In order to make their charges against her stick and confuse the electorate, these accusations are being made not only against Tsai, but also against Ho. Ultimately, the bloodymindedness of those in power could seriously undermine Taiwan’s biotechnology industry.
Although there are countless talented Taiwanese biotechnologists around the world, such vicious political attacks are likely to make them think twice before deciding to return to Taiwan.
People often bemoan the fact that Taiwan cares only about short-term profits and ignores the need to invest in fundamental research and development or the production of patents. As a result, most backward companies are forced to engage in original equipment manufacturing and earn meager profits, and are completely dependent on others for their survival.
The investment in Yu Chang represents the efforts of these scientists and Tsai to cultivate another lifeline for the long-term development and prosperity of the nation.
In terms of the Yu Chang controversy, the complexity of regulations and business maneuvers make it difficult for the public to gain a clear picture of the situation. Not to mention that certain media outlets have neglected to report the scientists’ defense of Tsai. Instead, they choose to question her repeatedly, a situation that infuriates me and makes me deeply concerned for the future.
That is why I decided to write this open letter to my former students. You are all capable of distinguishing right from wrong in this case and are unlikely to be deceived because you have access to a wide variety of information sources.
We need to support these scientists for the sake of Taiwan’s long-term future and a burgeoning biotechnology industry. This is not a matter of any specific political party or the pan-blue or pan-green camps; rather, it is about choosing what is good and shouldering the responsibility of what it means to be an intellectual.
Lo Chih-cheng is a legislative candidate for the Democratic Progressive Party.
Translated by Eddy Chang
Could Asia be on the verge of a new wave of nuclear proliferation? A look back at the early history of the North Atlantic Treaty Organization (NATO), which recently celebrated its 75th anniversary, illuminates some reasons for concern in the Indo-Pacific today. US Secretary of Defense Lloyd Austin recently described NATO as “the most powerful and successful alliance in history,” but the organization’s early years were not without challenges. At its inception, the signing of the North Atlantic Treaty marked a sea change in American strategic thinking. The United States had been intent on withdrawing from Europe in the years following
My wife and I spent the week in the interior of Taiwan where Shuyuan spent her childhood. In that town there is a street that functions as an open farmer’s market. Walk along that street, as Shuyuan did yesterday, and it is next to impossible to come home empty-handed. Some mangoes that looked vaguely like others we had seen around here ended up on our table. Shuyuan told how she had bought them from a little old farmer woman from the countryside who said the mangoes were from a very old tree she had on her property. The big surprise
The issue of China’s overcapacity has drawn greater global attention recently, with US Secretary of the Treasury Janet Yellen urging Beijing to address its excess production in key industries during her visit to China last week. Meanwhile in Brussels, European Commission President Ursula von der Leyen last week said that Europe must have a tough talk with China on its perceived overcapacity and unfair trade practices. The remarks by Yellen and Von der Leyen come as China’s economy is undergoing a painful transition. Beijing is trying to steer the world’s second-largest economy out of a COVID-19 slump, the property crisis and
As former president Ma Ying-jeou (馬英九) wrapped up his visit to the People’s Republic of China, he received his share of attention. Certainly, the trip must be seen within the full context of Ma’s life, that is, his eight-year presidency, the Sunflower movement and his failed Economic Cooperation Framework Agreement, as well as his eight years as Taipei mayor with its posturing, accusations of money laundering, and ups and downs. Through all that, basic questions stand out: “What drives Ma? What is his end game?” Having observed and commented on Ma for decades, it is all ironically reminiscent of former US president Harry